75th United States Congress

National Cancer Institute Awards ICF $49 Million Digital Communications Contract

Retrieved on: 
Thursday, July 22, 2021
Articles, Health, Academic disciplines, 75th United States Congress, National Cancer Institute, Public health, Smoking cessation, ICF International

FAIRFAX, Va., July 22, 2021 /PRNewswire/ --The National Cancer Institute (NCI) has awarded leading global consulting and digital services provider ICF (NASDAQ: ICFI) a single-award re-compete blanket purchase agreement (BPA) to provide digital communications strategy, design and implementation support for its behavioral health initiatives.

Key Points: 
  • FAIRFAX, Va., July 22, 2021 /PRNewswire/ --The National Cancer Institute (NCI) has awarded leading global consulting and digital services provider ICF (NASDAQ: ICFI) a single-award re-compete blanket purchase agreement (BPA) to provide digital communications strategy, design and implementation support for its behavioral health initiatives.
  • The BPA will be implemented by ICF Next, ICF's marketing, communications and digital transformation agency.
  • ICF will draw on its combined expertise in public health, digital communications, citizen engagement and behavior change to bring innovation to NCI's mobile health initiatives, including Smokefree.gov , to help the agency drive healthy actions.
  • This work will be supported by ICF experts in smoking cessation, communications with multicultural communities and communities that are underserved, and cancer control methods, practices, and resources.

AHN Cancer Institute Becomes One of Nation's First to Use Breakthrough Technology to Advance Radiation Therapy

Retrieved on: 
Friday, May 14, 2021
Cancer organizations, Medicine, Medical physics, 75th United States Congress, National Cancer Institute, Sidney Kimmel Comprehensive Cancer Center, Oncology, National Accreditation Program for Rectal Cancer, Radiation therapy

The MR-Linac is located at AHN\'s Cancer Institute hub at Allegheny General Hospital.\n"With the MR-Linac, we are able to offer patients the most sophisticated, effective and personalized radiation therapy possible for their specific diagnosis and tumor characteristics," said David Bartlett, MD , Chair, AHN Cancer Institute.

Key Points: 
  • The MR-Linac is located at AHN\'s Cancer Institute hub at Allegheny General Hospital.\n"With the MR-Linac, we are able to offer patients the most sophisticated, effective and personalized radiation therapy possible for their specific diagnosis and tumor characteristics," said David Bartlett, MD , Chair, AHN Cancer Institute.
  • "Investment in this unique technology is just another example of how we are transforming cancer treatment at AHN.
  • AHN Cancer Institute is a Quality Oncology Practice Initiative certified practice, and is accredited by the Foundation for Accreditation of Cellular Therapy, National Accreditation Program for Breast Centers and the National Accreditation Program for Rectal Cancer.
  • AHN also has a formal affiliation with the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, one of the nation\'s 41 comprehensive cancer centers designated by the National Cancer Institute, for research, medical education and clinical services.\n'

Sidney Kimmel Cancer Center at Jefferson Health Joins Caris Life Sciences' Precision Oncology Alliance

Retrieved on: 
Friday, May 14, 2021
75th United States Congress, National Cancer Institute, Health care, Healthcare in the United States, Medicine

b'IRVING, Texas, May 14, 2021 /PRNewswire/ --Caris Life Sciences, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced today that the Sidney Kimmel Cancer Center Jefferson Health (SKCC) has joined Caris\' Precision Oncology Alliance (POA).

Key Points: 
  • b'IRVING, Texas, May 14, 2021 /PRNewswire/ --Caris Life Sciences, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced today that the Sidney Kimmel Cancer Center Jefferson Health (SKCC) has joined Caris\' Precision Oncology Alliance (POA).
  • "\n"Physicians and researchers at SKCC have helped transform scientific discoveries into improved cancer treatments for their patients," said Chadi Nabhan , M.D., MBA, FACP,Chairman of the Caris Precision Oncology Alliance.
  • "\nThe Caris Precision Oncology Alliance includes 50 cancer centers and academic institutions.
  • To learn more, please visit CarisLifeSciences.com or follow us on Twitter ( @CarisLS ).\nThe National Cancer Institute (NCI)-designated Sidney Kimmel Cancer Center Jefferson Health (SKCC) is a nationally recognized center for practice-changing discovery and comprehensive cancer treatment, offering a depth and breadth of experience in all aspects of cancer from the laboratory to the clinic.

Shasqi Awarded Prestigious Direct-to-Phase-2 Small Business Innovation Research Grant by National Cancer Institute

Retrieved on: 
Tuesday, April 27, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medicine, Cancer, Clinical medicine, Oncology, Antineoplastic drugs, 75th United States Congress, National Cancer Institute, Chemotherapy

b'Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC\xe2\x84\xa2) Platform, announced today that it has been awarded a $2 million Direct-to-Phase-2 Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI).

Key Points: 
  • b'Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC\xe2\x84\xa2) Platform, announced today that it has been awarded a $2 million Direct-to-Phase-2 Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI).
  • \xe2\x80\x9cOur goal at Shasqi is to improve the safety and efficacy of novel and existing standard of care cancer drugs by directly activating them at the tumor.
  • The biopolymer is injected into the target tumor lesion, where it precisely activates an intravenously infused protodrug.
  • Shasqi leverages its proprietary CAPAC Platform to develop precision oncology therapeutics designed to improve efficacy while decreasing systemic toxicity.

Aura Biosciences Announces Publication of Data in Cancer Immunology Research, Supporting the Immune Mediated Mechanism of Action of the Virus-Like Drug Conjugate (VDC) Technology Platform with Broad Application in Cancer Treatment

Retrieved on: 
Wednesday, April 14, 2021
Science, Biotechnology, Research, Pharmaceutical, Optical, Oncology, Health, Clinical trials, 75th United States Congress, National Cancer Institute, Cancer, Eye neoplasm, Medicine, Causes of death, Health

The VDC technology platform is based on the discoveries of NIH Distinguished Investigator Dr. John Schiller of the Center for Cancer Research at the National Cancer Institute (NCI).

Key Points: 
  • The VDC technology platform is based on the discoveries of NIH Distinguished Investigator Dr. John Schiller of the Center for Cancer Research at the National Cancer Institute (NCI).
  • Aura has demonstrated the efficacy and safety of AU-011 in a Phase 1b/2 trial, including high rates of tumor control and vision preservation.
  • Future pipeline applications for Aura\xe2\x80\x99s technology include additional ocular oncology indications like choroidal metastases and solid tumor indications like non-muscle invasive bladder cancer.
  • For more information, visit www.aurabiosciences.com or follow us on Twitter .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210414005113/en/\n'

Oncocyte Announces Formation of Medical Advisory Board

Retrieved on: 
Tuesday, March 9, 2021
75th United States Congress, National Cancer Institute, Oncology, Medical specialties, Health care

Dr. Gandara is the principal investigator for a National Cancer Institute (NCI) UG1 award to UCDCCC for Cancer Clinical Trials.Dr.

Key Points: 
  • Dr. Gandara is the principal investigator for a National Cancer Institute (NCI) UG1 award to UCDCCC for Cancer Clinical Trials.Dr.
  • Gandara has also been a Scientific and Medical Advisor to Oncocyte.
  • I look forward to working with them and my fellow board members on a potential expansion into other critical cancer indications.
  • These statements include those pertaining to the Oncocyte Medical Advisory Board, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management.

Debbie's Dream Foundation Hosted a Successful 9th Annual Stomach Cancer Capitol Hill Advocacy Day

Retrieved on: 
Monday, March 8, 2021
Cancer, 75th United States Congress, National Cancer Institute, Cancer research, Medicine, Health care

WASHINGTON, March 8, 2021 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) hosted its 9th Annual Stomach Cancer Capitol Hill Advocacy Day virtually on February 11 and 12, 2021.

Key Points: 
  • WASHINGTON, March 8, 2021 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) hosted its 9th Annual Stomach Cancer Capitol Hill Advocacy Day virtually on February 11 and 12, 2021.
  • These consistent efforts help ensure that stomach cancer remains eligible for funding through the Department of Defense's Peer Reviewed Cancer Research Program (PRCRP).
  • This year's Advocacy Day was held just two months following the National Cancer Institute's (NCI) December 2020 announcement to approve the concept of a new gastric cancer research program dedicated to advancing knowledge of the origins of stomach cancer.
  • Debbie is considered a pioneer by many for bringing awareness to the plight of stomach cancer patients worldwide and the lack of federal funding for stomach cancer research.

FGA Urges Department of Labor Not to Delay Implementation of the Independent Contractor Status Under the Fair Labor Standards Act

Retrieved on: 
Wednesday, February 24, 2021
Taxation in the United States, 75th United States Congress, Child labor in the United States, Child labour law, Fair Labor Standards Act, Minimum wage law, FLSA, Independent contracting in the United States, Foundation for Government Accountability, United States Department of Labor, Articles, Economy

NAPLES, Fla., Feb. 24, 2021 /PRNewswire-PRWeb/ --The Foundation for Government Accountability (FGA) responds to the Department of Labor's delay in implementation of the Independent Contractor Status Under the Fair Labor Standards Act.

Key Points: 
  • NAPLES, Fla., Feb. 24, 2021 /PRNewswire-PRWeb/ --The Foundation for Government Accountability (FGA) responds to the Department of Labor's delay in implementation of the Independent Contractor Status Under the Fair Labor Standards Act.
  • FGA encourages DOL not to delay the effective date as the rule provides much-needed clarity to the "economic realities" test which determines whether a worker is a contractor or employee.
  • The independent contractor rule ends inconsistencies between federal courts by providing a formal independent contractor classification under the Fair Labor Standards Act (FLSA).
  • FGA is joined by the Coalition to Promote Independent Entrepreneurs as they call for the implementation of the Independent Contractor Rule.

Cybrexa Therapeutics Enters Cooperative Research and Development Agreement (CRADA) with U.S. National Cancer Institute to Develop CBX-12 (alphalex™- exatecan)

Retrieved on: 
Wednesday, February 24, 2021
Health care, 75th United States Congress, National Cancer Institute, Healthcare in the United States

Under terms of the agreement, Cybrexa and the NCI will collaborate on pre-clinical and potential clinical development of Cybrexas lead therapeutic candidate, CBX-12 (alphalex-exatecan).

Key Points: 
  • Under terms of the agreement, Cybrexa and the NCI will collaborate on pre-clinical and potential clinical development of Cybrexas lead therapeutic candidate, CBX-12 (alphalex-exatecan).
  • This research and development agreement with the NCI is not only a validation of Cybrexas technology, but may also allow us to significantly expand our clinical development program, said Per Hellsund, President and CEO of Cybrexa.
  • Collaborating with the NCI on the development of CBX-12 may allow testing of its therapeutic potential by some of the worlds leading oncology researchers.
  • Cybrexa is a privately-held biotechnology company dedicated to developing next-generation tumor-targeted cancer therapies using its alphalex platform.

FemTech Company MobileODT awarded prestigious National Cancer Institute (NCI) grant

Retrieved on: 
Wednesday, January 20, 2021
75th United States Congress, National Cancer Institute, Cancer, Cancer screening, Cervical cancer, Medical specialties, Clinical medicine

TEL AVIV, Israel, Jan. 20, 2021 /PRNewswire/ -- MobileODT , a FemTech company producing the latest digital innovation in cervical screening, has been awarded a prestigious Small Business Innovation Research Authority grant of $2.3 million.

Key Points: 
  • TEL AVIV, Israel, Jan. 20, 2021 /PRNewswire/ -- MobileODT , a FemTech company producing the latest digital innovation in cervical screening, has been awarded a prestigious Small Business Innovation Research Authority grant of $2.3 million.
  • This grant is presented by the United States National Cancer Institute (NCI) to leading companies that are technologically and clinically advanced to support the NCI's goal of reducing suffering and death due to cancer.
  • This grant is a tribute to the groundbreaking advances of MobileODT as an innovative company commercializing a novel cervical cancer screening technology utilizing complex machine learning (ML) and artificial intelligence (AI) algorithms.
  • "We are honored to receive such a prestigious grant, especially from National Cancer Institute.